HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Edrophonium
Edrofonio cloruro [DCIT] · ethyl-(3-hydroxyphenyl)-dimethylazanium · N-Ethyl-3-hydroxy-N,N-dimethylbenzenaminium
Identifikatoren & physikalische Daten
| CAS No. | 116-38-1 |
|---|---|
| Summenformel | C10H16NO+ |
| Durchschnittliche Molmasse | 166,24 g/mol |
| Monoisotopische Masse | 166,12318913 g/mol |
| SMILES | CC[N+](C)(C)c1cccc(O)c1 |
| InChIKey | VWLHWLSRQJQWRG-UHFFFAOYSA-O |
| PubChem CID | 3202 |
| ChEMBL | CHEMBL1104 |
| ChEBI | CHEBI:251408 |
| DTXSID | DTXSID4046943 |
Chemische & physikalische Eigenschaften
| XLogP | 1,8 |
|---|---|
| Polarare Oberfläche (TPSA) | 20,2 |
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 1 |
| Frei drehbare Bindungen | 2 |
| Schwere Atome | 12 |
| Formalladung | 1 |
| Komplexität | 145 |
| LogP (Verteilungskoeffizient) | -2.95 |
| Löslichkeit | Appreciable as liquid hydrochloride salt4.86e-02 g/L |
| Schmelzpunkt | 162-163 |
| Physical Description | Liquid |
Sicherheit & Vorschriften
| Unerwünschte Wirkungen | The adverse effects of edrophonium occur due to the increased levels of acetylcholine binding to muscarinic acetylcholine receptors. The more serious adverse effects are cardiac arrhythmias, especially bradycardia, atrioventricular block, and cardiac arrest. The muscarinic cholinergic adverse effects also include bronchoconstriction due to airway smooth muscle contraction secondary to increased stimulation of muscarinic receptors. Other adverse effects include bronchial secretions, diarrhea, salivation, lacrimation, increased urinary frequency and urgency, and miosis. Clinicians can attenuate most of the adverse effects with the simultaneous administration of atropine, which functions as a muscarinic receptor antagonist to prevent developing these cholinergic adverse effects. |
|---|---|
| Toxizitätsübersicht | Overdose of edrophonium will result in muscarinic symptoms due to the cholinergic crisis manifested by excessive acetylcholine binding to muscarinic receptors. The cholinergic crisis includes diarrhea, increased urination, miosis, muscle weakness, bronchospasm, bradycardia, emesis, and lacrimation. The more serious outcomes of edrophonium overdose involve respiratory muscle weakness and cardiac arrhythmias that can progress to a fatal outcome. Hence, clinicians must ensure patent airway and circulation. The treatment of an edrophonium overdose is atropine. Atropine is an ideal antidote for edrophonium since it has a similar onset of action as edrophonium. Atropine functions by competitively inhibiting the muscarinic receptors on structures innervated by postganglionic cholinergic nerves and inhibiting muscarinic receptors on smooth muscle. Atropine can be administered up to 1.2 mg intravenously initially and repeated every 20 minutes until secretions are controlled. If convulsions are present, clinicians should institute appropriate supportive measures. For convulsions, supportive treatment is required. |
| Drug Induced Liver Injury | Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)edrophoniumEnlon®CholinergicsNot Applicableno-DILI-concern |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during LactationEdrophonium is no longer marketed in the US. No information is available on the use of edrophonium during breastfeeding. However, because of its short half-life and quaternary ammonium structure, it is unlikely to be excreted into breastmilk or orally absorbed by the infant. Administering the drug just after breastfeeding and waiting 2 to 3 hours before breastfeeding again should avoid any adverse reactions in the infant.◉ Effects in Breastfed InfantsRelevant published information was not found as of the revision date.◉ Effects on Lactation and Breastmilk |
Anwendungen & Verwendung
Verwenden
Antidote (to curare principles); diagnostic aid (myasthenia gravis).